Validity and reliability of VO2-max testing in persons with Parkinson's disease

Effect of Aerobic Exercises on Lung Function in Women With Fibromyalgia: A Randomized Controlled Trial

BACKGROUND

Aerobic exercises (AEs) have gained much interest in managing fibromyalgia (FM). This trial aimed to find out how AEs affect women with FM in terms of lung function, chest expansion, dyspnea, exercise capacity, and quality of life.

METHODS

Eighty FM-diagnosed women were allocated randomly into 2 equal-sized groups. For 12 weeks, the AEs group did moderate-intensity aerobic cycling and diaphragmatic breathing exercises while the control group did just diaphragmatic breathing exercises. Outcome measures included forced vital capacity, forced expiratory volume in the first second, and total lung capacity for lung function; upper and lower chest expansions; Medical Research Council dyspnea scale for dyspnea; maximal oxygen consumption for exercise capacity; and physical component score and mental component score components of the 12-item Short Form Health Survey for quality of life.

RESULTS

By study completion, all outcomes improved significantly in the AEs and control groups (P < .05). Compared with the group of control, the AEs group revealed more substantial increases in forced vital capacity (9.51% vs 4.95%, P = .04), forced expiratory volume in the first second (8.72% vs 4.54%, P = .03), total lung capacity (11.02% vs 5.39%, P = .001), upper chest expansion (21.22% vs 10.03%, P = .02), lower chest expansion (31.35% vs 11.2%, P = .01), maximal oxygen consumption (55.89% vs 36.94%, P = .03), physical component score (18.8% vs 10.9%, P = .001), and mental component score (25.67% vs 15.26%, P = .02) accompanied with greater declines in Medical Research Council dyspnea scale scores (37.71% vs 19.45%, P = .03).

CONCLUSIONS

In FM women, moderate AEs could improve lung function, chest expansion, dyspnea, exercise capacity, and quality of life.

Influence of Aerobic Exercise on Functional Capacity and Maximal Oxygen Uptake in Patients With Parkinson Disease: A Systematic Review and Meta-analysis

OBJECTIVE

To determine the effects of aerobic training in randomized controlled clinical trials on functional capacity, motor symptoms, and oxygen consumption in individuals with Parkinson disease (PD) through a systematic literature review and meta-analysis.

DATA SOURCES

PUBMED, Web of Science, CINAHL, SciELO, and Medline databases were searched to identify published studies until September 2023.

STUDY SELECTION

Randomized controlled clinical trials that evaluated the long-term effect of aerobic exercise in individuals with PD were included.

DATA EXTRACTION

Two independent reviewers extracted the data and assessed the risk of bias and the Grading of Recommendation Assessment, Development, and Evaluation. In case of disagreement, a third reviewer was consulted.

DATA SYNTHESIS

Thirteen studies were included in the systematic review, and the number of participants was 588 with an average age of 66.2 years (57-73y). The study's exercise intervention lasted between 6 and 70 weeks, with most studies lasting 10-12 weeks, with 3 sessions per week and an average duration of 47 minutes per session. The meta-analysis revealed that aerobic exercise is effective in enhancing maximal oxygen uptake (standardized mean difference, SMD 0.42 [95% CI, 0.18, 0.66; P=.0007]) and functional capacity (SMD 0.48 [95% CI, 0.24-0.71; P<.0001]). In addition, aerobic exercise can reduce the motor-unified Parkinson disease rating scale (mean difference-2.48 [95% CI, -3.16 to -1.81; P<.00001]) score in individuals with PD.

CONCLUSIONS

Aerobic exercise training conducted 2-3 times a week, with different intensities (low to high), can be an effective intervention for enhancing functional capacity, maximizing oxygen uptake, and reducing the UPDRS scores in individuals with PD.

Test-retest reliability of cardiopulmonary exercise test-derived metrics in individuals with COPD versus healthy controls

BACKGROUND

Cardiopulmonary exercise testing (CPET) is usually considered the gold standard for assessing maximal oxygen consumption (V̇O2max), a health and performance marker in patients with chronic obstructive pulmonary disease (COPD). Despite the widespread application of CPET, the absolute and relative test-retest reliability of CPET-derived metrics remains unexamined.

OBJECTIVE

To examine and compare test-retest reliability of CPET derived metrics in individuals with COPD and healthy matched controls.

METHODS

12 individuals with COPD and 12 healthy age- and sex-matched controls were included in this case-control study. Each participant completed two CPET on a bicycle ergometer on two different days. Absolute reliability was reported as smallest real difference (SRD) and relative reliability as coefficient of variance (CV) and intraclass correlation coefficients (ICC).

MAIN RESULTS

SRD for peak oxygen uptake was 451.6 (267.4;1006.4) mL/min and CV was 7.8 (4.7;11.0)% in patients with COPD, whereas SRD was 244.2 (151.4;491.5) mL/min and CV was 3.0 (1.8;4.2)% in healthy controls but with no significant between group difference for SRD. CV values for all CPET derived metrics were found to be below 10%. Apart from peak workload achieved and peak minute ventilation, SRD and CV were significantly higher in COPD than in controls for all other CPET-derived metrics.

CONCLUSION

This study provides test-retest reliability estimates of the most widely used CPET derived metrics in individuals with COPD and healthy matched controls. Test-retest reliability for most metrics derived from CPET were found to be lower in individuals with COPD when compared to healthy controls.

Reliability and validity of the two-minute step test in patients with total knee arthroplasty

PURPOSE

To investigate the test-retest reliability and concurrent validity of 2MST for assessing the physical performance of patients with total knee arthroplasty (TKA).

MATERIALS AND METHODS

Fifty-one patients with TKA, aged more than 18 years, of both sexes, and underwent a primary TKA at least six months ago, were included in this study. The intraclass correlation coefficient (ICC) and 95% confidence interval (CI), standard error of measurement (SEM), and minimum detectable change at the 95% confidence level (MDC95) were used to determine the reliability of 2MST. In the validity, the correlations of the 2MST between the six-minute walk test (6MWT) and the two-minute walk test (2MWT) were assessed.

RESULTS

The reliability of 2MST was excellent (ICC = 0.97, SEM = 2.76, MDC95 = 7.6). There was a moderate correlation between 2MST and 6MWT (r = 0.586; p = 0.000), as well as between 2MST and 2MWT (r = 0.633; p = 0.000).

CONCLUSIONS

2MST proved to be a reliable and valid physical performance test in patients with TKA. 2MST can be used to evaluate the physical performance of TKA patients.ClinicalTrials.gov Identifier: NCT05064943.

Are physical activity levels, cardiorespiratory fitness and peak power associated with Parkinson's disease severity?

INTRODUCTION

Increased physical activity (PA) may slow Parkinson's disease (PD) progression. Associations between markers of PA and PD severity could justify further studies evaluating interventions increasing PA levels in PD. The objectives of the present study were to assess associations between PA, cardiorespiratory fitness (VO2-max), and muscle peak power and measures of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the Parkinson's disease questionnaire-39 (PDQ-39), and the four PD hallmark motor symptoms (rigidity, bradykinesia, postural instability, and tremor).

METHODS

Data from 105 people with PD were used. PA was measured for seven consecutive days using accelerometers. Peak power was measured with a linear encoder during a chair rise test, while VO2-max was directly assessed during a graded bicycle test. Analyses included simple and multiple linear regression and hurdle exponential regression.

RESULTS

PA was weakly to moderately associated with MDS-UPDRS II + III, rigidity, bradykinesia, and postural instability, as well as PDQ-39 mobility and activities of daily living sub-scores. VO2-max and peak power were weakly to moderately associated with MDS-UPDRS III, bradykinesia, and postural instability, while peak power was further weakly associated with the MDS-UPDRS II. Lastly, VO2-max was associated with PDQ-39 mobility and activities of daily living sub-scores.

CONCLUSION

PA, VO2-max, and peak power were associated with PD severity, thus highlighting the potential benefits of a physically active lifestyle. Furthermore, PA and VO2-max were associated with PDQ-39 sub-scores. This calls for confirmation of the potential effect of PA on quality of life in PD.

Validity and reliability of linear encoder muscle power testing in persons with Parkinson's disease

OBJECTIVE

To investigate the construct validity ON medication and the reliability both ON and OFF medication of linear encoder muscle power testing in persons with Parkinson's disease (pwPD).

DESIGN

A study using baseline data from one randomized controlled trial (study 1) and one cohort study (study 2).

SETTING

University exercise lab.

PARTICIPANTS

Study 1: 35 healthy controls and 70 pwPD. Study 2: 20 pwPD.

INTERVENTION

Study 1: baseline data. Study 2: 4 chair rise tests (2 ON and 2 OFF medication), in a randomized order, separated by 4 to 16 days.

MAIN MEASURES

Linear encoder data were collected from a chair rise test. Known groups validity and convergent validity (i.e., construct validity) were assessed by comparing peak power between pwPD and healthy controls and associations between peak power and functional performance (i.e., 6-Min Walk Test, Timed Up and Go Test, Six-Spot Step Test), respectively. Reliability was assessed as day-to-day variation and by intraclass correlation coefficients.

RESULTS

Peak power was comparable between pwPD and healthy controls (-7.2%, p = 0.17), but lower in moderately impaired pwPD compared to mildly impaired pwPD (-27%, p < 0.01) and healthy controls (-23%, p < 0.01). Moderate to strong associations were observed between peak power and functional performance (r2 = 0.44-0.51). Day-to-day variation ON and OFF medication were 1.0 and 1.3 W/kg, respectively, while intraclass correlation coefficients were 0.95 (0.87;0.98) and 0.93 (0.82;0.97), respectively.

CONCLUSION

Linear encoder muscle power testing shows inconsistent known groups validity, acceptable convergent validity ON medication, and excellent day-to-day reliability ON and OFF medication in pwPD.